论文部分内容阅读
日前,在武汉大学中国科学评价研究中心(Research Center for Chinese Science Evaluation,RCCSE)推出的第四届“RCCSE中国核心学术期刊”评价中,《中国肿瘤临床》首次被评为“RCCSE中国核心学术期刊(A)”。这是国内有影响力的科学评价机构又一次对本刊的高度评价和肯定。RCCSE是我国高等院校中第一个综合性科学评价研究中心,是国内期刊评价的权威机构,结合文献计量学与专家评审两方面对期刊学术质量和影响力进行定量与定性评估。定量选取的指标主要有:基金论文比、总被引频次、影响因子、web(网页)下载率等。中国核心学术期刊(A)为评价总分排在5%~20%的期刊,占各学科期刊总数的15%。入选RCCSE核心期刊,说明《中国肿瘤临床》办刊质量和水平不断进步,在同行中的竞
Recently, China Cancer Clinical Research was named “RCCSE China” for the first time in the 4th “RCCSE China Core Academic Journal” evaluation launched by the Research Center for Chinese Science Evaluation (RCCSE) at Wuhan University. Core academic journals (A) “. This is the domestic influential scientific evaluation agency once again highly praised the magazine. RCCSE is the first comprehensive scientific evaluation research center in China’s colleges and universities. It is the authoritative institution of domestic periodical evaluation. Combined with the bibliometrics and expert evaluation, RCCSE quantitative and qualitative assessment of the academic quality and influence of the periodicals. Quantitative selection of the main indicators are: fund thesis ratio, the total cited frequency, impact factor, web (web) download rate. China’s core academic journals (A) to evaluate the total score of 5% to 20% of journals, accounting for 15% of the total number of journals. Selected RCCSE core journals, indicating that ”China’s cancer clinical" quality and level of continuous improvement in the peer competition